{"id":"W4293565846","doi":"10.1016/j.jtocrr.2022.100400","title":"BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Alberta Health Services; McMaster University; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Alberta","funders":"Genentech; Astellas Pharma; Regeneron Pharmaceuticals; Ipsen; BeiGene; Merck KGaA; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Adverse effect; Combination therapy; Internal medicine; Pharmacokinetics; Refractory (planetary science); Oncology; Confidence interval; Progression-free survival; Phases of clinical research; Clinical endpoint; Gastroenterology; Pharmacology; Chemotherapy; Immunotherapy; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001446367,0.001319939,0.002214739,0.0006271779,0.0003344998,0.0008595682,0.0006721987,0.001091898,0.002169627],"category_scores_gemma":[0.0006180949,0.0004503237,0.001568727,0.0005355026,0.0006435884,0.0007878397,0.0002277059,0.001908117,0.0008755716],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008429567,"about_ca_system_score_gemma":0.0009339222,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00110967,"about_ca_topic_score_gemma":0.003426117,"domain_scores_codex":[0.99963,0.00015012,0.00003456608,0.00006348339,0.00006046327,0.00006147954],"domain_scores_gemma":[0.9995785,0.00007009904,0.00008099442,0.00002797398,0.00004436287,0.0001980319],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4964247,0.06107271,0.01489143,0.002921629,0.004847159,0.0005154807,0.0005264254,0.002777706,0.1106656,0.0001970354,0.007101568,0.2980585],"study_design_scores_gemma":[0.3903529,0.5460473,0.04200627,0.0001998401,0.002433585,0.0009199778,0.0001401286,0.001938657,0.01085091,0.0001747246,0.004860912,0.00007474721],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902799,0.006827983,0.0002042148,0.0002659615,0.00008269253,0.0005494679,0.0006309801,0.0000783366,0.00108051],"genre_scores_gemma":[0.9884794,0.006198359,0.0007199969,0.0006489926,0.0001693462,0.0005070756,0.001909451,0.00003966563,0.001327822],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002214739,"threshold_uncertainty_score":0.007649183,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07985497471285384,"score_gpt":0.466754628081248,"score_spread":0.3868996533683942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}